Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that NephroPlus Health Services Kazakhstan LLP, an overseas subsidiary of the Company has entered into a Share Purchase ....

Ref: NEPHROPLUS/SE/82 September 1, 2026 To To BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Listing Centre Through: NEAPS Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) - Acquisition of 100% participatory interest in “Dialysis Center Almaty” LLP, Kazakhstan Dear Sir/Madam, Pursuant to Regulation 30 and other applicable provisions of the SEBI Listing Regulations, we hereby inform that NEPHROPLUS HEALTH SERVICES KAZAKHSTAN LLP (“NPHSK LLP”), an overseas step-down subsidiary of Nephrocare Health Services Limited (“Company”), has, on September 1, 2026, entered into a Sale and Purchase Agreement (“SPA”) with Ms. Aizhan Slambekovna Zhambulova (“Seller”) for acquisition of 100% participatory interest in the charter capital of “Dialysis Center Almaty” LLP (“Target Entity”), a limited liability partnership incorporated under the laws of the Republic of Kazakhstan. The aggregate consideration payable for the acquisition is KZT 561.66 million (Kazakhstani Tenge Five Hundred Sixty-One Million Six Hundred Sixty-Three Thousand Five Hundred Ten only) (Approx. ₹116.35 million), subject to such downward adjustments as may be applicable in accordance with the terms of the SPA. The completion of the acquisition is subject to fulfilment or waiver, as applicable, of the conditions precedent and completion of the closing actions contemplated under the SPA. Upon completion of the transaction, NPHSK LLP will hold 100% participatory interest in the Target Entity, and consequently, the Target Entity will become an overseas step-down subsidiary of the Company. The acquisition is in line with the Company’s strategy of expanding its dialysis services network in international markets and will further strengthen the Company’s presence in Kazakhstan. The details required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI Master Circular are enclosed as Annexure I. The aforesaid information is also being made available on the website of the Company www.nephroplus.com. For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary & Head Legal ICSI M. No. F9895 ANNEXURE I Sr. Particulars Description 1. Name of the target entity, details in Dialysis Center Almaty LLP (“Target Entity”), a brief such as size, turnover etc. limited liability partnership incorporated under the laws of the Republic of Kazakhstan. The Target Entity is engaged in the business of providing dialysis services through its dialysis centres in Kazakhstan. Last audited turnover of the Target Entity is KZT 527.44 million (approx. ₹10.93 crore). 2. Whether the acquisition would fall The acquisition does not constitute a related within related party transaction(s) party transaction. The Promoter, Promoter and whether the promoter/promoter Group and/or Group Companies of the group/group companies have any Company do not have any interest in the Target interest in the entity being acquired? Entity or the Seller. If yes, nature of interest and details thereof and whether the same is done at “arm’s length”. 3. Industry to which the entity being Healthcare – Dialysis services. acquired belongs. 4. Objects and impact of acquisition The acquisition is in line with the Company’s (including but not limited to, existing business and its strategy of expanding disclosure of reasons for acquisition its dialysis services network in international of target entity, if its business is markets. The acquisition is expected to outside the main line of business of strengthen the Company’s presence and the listed entity). operating platform in Kazakhstan and support the further expansion of its dialysis services business in the region. 5. Brief details of any governmental or The acquisition and transfer of the participatory regulatory approvals required for the interest are subject to completion of the acquisition. applicable statutory and regulatory formalities under the laws of the Republic of Kazakhstan, including state re-registration of the Target Entity in connection with the transfer of the participatory interest to NPHSK LLP, and such other approvals/registrations, if any, as may be applicable. 6. Indicative time period for completion The acquisition will be completed upon of the acquisition. satisfaction or waiver, as applicable, of the conditions precedent and completion of the closing actions contemplated under the SPA. 7. Consideration - whether cash Cash consideration. consideration or share swap or any other form and details of the same. 8. Cost of acquisition and/or the price KZT 561.66 million (Kazakhstani Tenge Five at which the shares are acquired. Hundred Sixty-One Million Six Hundred Sixty- Three Thousand Five Hundred Ten only) (Approx. ₹116.35 million), subject to downward adjustments, if any, in accordance with the terms of the SPA. 9. Percentage of shareholding/control 100% participatory interest in the charter capital acquired and/or number of shares of the Target Entity. Upon completion of the acquired. acquisition, NPHSK LLP will hold 100% of the participatory interest in and exercise control over the Target Entity. 10. The Target Entity was incorporated on February Brief background about the entity 22, 2019 under the laws of the Republic of acquired in terms of products/line of Kazakhstan and is engaged in providing dialysis business acquired, date of services through its dialysis centres. It operates incorporation, history of last three in Kazakhstan and has 34 dialysis machines. years’ turnover, country in which the acquired entity has presence and any Turnover for the last three financial years: other significant information (in brief). Calendar Year 2023: KZT 435.35 million (approx. ₹9.02 crore) Calendar Year 2024: KZT 493.83 million (approx. ₹10.23 crore) Calendar Year 2025: KZT 527.44 million (approx. ₹10.93 crore)